Stock comparison
Regeneron Pharmaceuticals
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
REGN
Regeneron Pharmaceuticals
Market cap
$65.82B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | REGN | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 71B | UTHR |
| Benjamin Graham | 68B | 76B | UTHR |
| Philip Fisher | 48D | 76B | UTHR |
| Peter Lynch | 26F | 62C | UTHR |
| Joel Greenblatt | 45D | 46D | UTHR |
| Charlie Munger | 59C | 64C | UTHR |
| Terry Smith | 57C | 64C | UTHR |
Side-by-side metrics
| Metric | REGN | UTHR |
|---|---|---|
| Market cap | $65.82B | $24.13B |
| P/E (TTM) | 16.4x | 19.2x |
| EV/EBIT | 20.0x | 15.2x |
| ROIC (TTM) | 8.53% | 18.81% |
| Gross margin | 84.55% | 86.58% |
| Net margin | 29.65% | 40.61% |
| Revenue CAGR 5y | -2.81% | 17.22% |
| EPS CAGR 5y | -13.35% | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.51% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
REGN leads on
- Dividend yield0.51%vs 0.0%+100%
- Market cap$65.82Bvs $24.13B+63%
- P/E (TTM)16.4xvs 19.2x+15%
UTHR leads on
- EPS CAGR 5y29.84%vs -13.35%+145%
- Revenue CAGR 5y17.22%vs -2.81%+116%
- Debt / Equity-vs 0.1x+100%
- ROIC (TTM)18.81%vs 8.53%+55%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.